Nektar Therapeutics (NKTR)

Nektar Therapeutics' stock price has increased by 93.7% since the start of the year and 827.35% over the past year. Key events include positive Phase 2 data readouts for rezpegaldesleukin, public offerings in February and April 2026, positive 52-week extension results from REZOLVE-AA, Q1 2026 financial results showing a narrowed net loss, and plans to initiate Phase 3 programs for rezpegaldesleukin in atopic dermatitis and alopecia areata.

As a clinical-stage biopharmaceutical company, Nektar Therapeutics does not experience direct product demand seasonality. Revenue is derived from non-cash royalty revenue and collaborations rather than widespread product sales. Stock performance seasonality reflects investor behavior and market trends.

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on drug discovery and development using its PEGylation and advanced polymer conjugate technologies. The company creates immunomodulatory agents targeting autoimmune diseases, inflammatory conditions, and cancer. Key product candidates include rezpegaldesleukin (REZPEG, or NKTR-358), NKTR-0165, NKTR-0166, NKTR-422, and NKTR-255.

Nektar Therapeutics is headquartered in San Francisco, California, but its clinical trials have a global reach. Phase 3 studies include patient enrollment from North America (15%-25%), Europe (40%-55%), and the Asia-Pacific (APAC) region (20%-30%), involving around 150 sites per study.

Nektar Therapeutics' brand reputation has been positively influenced by successful Phase 2 data readouts for rezpegaldesleukin, demonstrating durable efficacy and potential for complete disease clearance. Significant capital raised through public offerings also contributes to a favorable perception. No specific negative events impacting the brand reputation were reported in the past year.

Institutional ownership in Nektar Therapeutics ranges from 68% to 75.88%, with 193 institutional owners holding 17,705,201 shares as of May 5, 2026. Major institutional owners include BVF Inc/il, Vanguard Group Inc, and BlackRock, Inc. Individual investors hold approximately 25% of the company's stake, while insiders own less than 1%.